PeptiDream (4587) Q3 2024 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2024 rose 84.5% year-over-year to ¥41.6 billion, driven by strong growth in the Drug Discovery and Development segment.

• Core operating profit surged 250.2% to ¥24.7 billion, with profit attributable to owners of parent up 397.6% to ¥17.6 billion.

• The company advanced both its Radiopharmaceutical and Non-Radiopharmaceutical Drug Discovery businesses, with multiple clinical and preclinical programs progressing.

• Cash and cash equivalents increased to ¥50.4 billion, reflecting robust operating and investing cash flows.

Financial highlights

• Gross profit for the period was ¥32.5 billion, up from ¥14.2 billion year-over-year.

• Operating profit reached ¥24.5 billion, a 263.1% increase from the prior year.

• Basic earnings per share rose to ¥135.95 from ¥27.30 year-over-year.

• Total assets grew to ¥93.4 billion, with equity attributable to owners of parent at ¥58.5 billion.

• Cash flows from operating activities were ¥23.8 billion, up ¥14.7 billion year-over-year.

Outlook and guidance

• Full-year 2024 revenue is forecast at ¥45.0 billion, up 56.7% year-over-year.

• Core operating profit is projected at ¥20.5 billion, with profit attributable to owners of parent at ¥14.0 billion.

• No revisions have been made to the most recent financial forecast.